Business Context and Reporting Period
Company: Microbot Medical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 27, 2025
Reporting Period: August 26, 2025 through August 27, 2025
Business Context: The filing reports the unregistered sale of equity securities via the exercise of preferred investment options.
Key Financial Metrics
- Gross Proceeds: Approximately $8.6 million (before deducting placement agent fees and expenses).
- Shares Issued: 4,055,870 shares of Common Stock.
- Outstanding Shares: Approximately 52,569,762 shares as of August 27, 2025.
- Exercise Prices: $2.10 per share for Series H Options; $2.13 per share for Series I Options.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational metrics.
Material Changes
The primary material change is the increase in outstanding common stock resulting from the exercise of 300,000 Series H Options and 3,755,870 Series I Options. This transaction generated capital for the company and increased the total share count to approximately 52.57 million.
Guidance, Outlook, and Risks
- Transaction Details: Shares were issued pursuant to the exemption provided in Section 4(a)(2) under the Securities Act of 1933 as transactions not involving a public offering.
- Resale Registration: Shares underlying the Series H Options are registered for resale on Form S-3 (No. 333-284688). Shares underlying the Series I Options are registered for resale on Form S-3 (No. 333-285690).
- Guidance and Outlook: The filing text does not provide a clear value for future guidance or management commentary.
- Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Verify the exact amount of placement agent fees and expenses deducted from the $8.6 million gross proceeds to determine net cash inflow.
- Confirm the dilution impact of the 4,055,870 new shares on existing shareholders.
- Review the referenced Form S-3 registration statements (333-284688 and 333-285690) for resale restrictions or lock-up periods.
- Check subsequent filings for the company's updated cash position and burn rate following this capital raise.